<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129385">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01842776</url>
  </required_header>
  <id_info>
    <org_study_id>20129159</org_study_id>
    <nct_id>NCT01842776</nct_id>
  </id_info>
  <brief_title>Care Transitions in Renal Disease Patients</brief_title>
  <acronym>CT</acronym>
  <official_title>Care Transitions in Renal Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Medical Care North America</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fresenius Medical Care North America</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this pilot is to reduce the 30-day hospital readmission rate for dialysis
      patients. It is a quality improvement project that consistent of 4 &quot;tracks.&quot;  Tracks 1 &amp; 2:
      Implement use of checklists of activities for staff to complete when patients are admitted
      to the hospital, and post-hospitalization with emphasis on fluid assessment, nutrition
      management, patient coaching, and communication between institutions. Track 3: Work with
      physicians to develop process to individualize post-hospitalization dialysis orders and
      improve medication reconciliation. Track 4: Use a renal Care Transitions Case Manager to
      follow patients in the hospital and 30 days post-hospitalization to facilitate care and
      patient coaching.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>30-day readmission rate</measure>
    <time_frame>Participants will be followed for the duration of each hospital stay and 30 days post-hospitalization, for an expected average of 37 days.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of hospitalizations that occur within 30 days after discharge from an initial index hospitalization (convert to percentage of 30-day readmissions).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3300</enrollment>
  <condition>Renal Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adult hemodialysis patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic hemodialysis patients

          -  All patients admitted to the hospital during the study period

        Exclusion Criteria:

          -  Patients &lt;18 years old
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rebecca L Wingard, RN, MSN</last_name>
    <phone>615-567-4846</phone>
    <email>rebecca.wingard@fmc-na.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathryn McDougall, RN, BSN</last_name>
    <phone>615-567-4837</phone>
    <email>kathryn.mcdougall@fmc-na.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fresenius</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca L Wingard, RN, MSN</last_name>
      <phone>615-567-4846</phone>
      <email>rebecca.wingard@fmc-na.com</email>
    </contact>
    <investigator>
      <last_name>Franklin Maddux, MD, FACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 25, 2013</lastchanged_date>
  <firstreceived_date>April 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
